RÉSUMÉ
BACKGROUND: Right ventricular (RV) function plays a critical role in the pathophysiology and acute prognosis of pulmonary embolism (PE). We analyzed the temporal changes of RV function in the cohort of a prospective multicentre study investigating if an early switch to oral anticoagulation in patients with intermediate-risk PE is effective and safe. METHODS: Echocardiographic and laboratory examinations were performed at baseline (PE diagnosis), 6 days and 6 months. Echocardiographic parameters were classified into categories representing RV size, RV free wall/tricuspid annulus motion, RV pressure overload and right atrial (RA)/central venous pressure. RESULTS: RV dysfunction based on any abnormal echocardiographic parameter was present in 84% of patients at baseline. RV dilatation was the most frequently abnormal finding (40.6%), followed by increased RA/central venous pressure (34.6%), RV pressure overload (32.1%), and reduced RV free wall/tricuspid annulus motion (20.9%). As early as day 6, RV size remained normal or improved in 260 patients (64.7%), RV free wall/tricuspid annulus motion in 301 (74.9%), RV pressure overload in 297 (73.9%), and RA/central venous pressure in 254 (63.2%). At day 180, the frequencies slightly increased. The median NT-proBNP level decreased from 1448 pg/ml at baseline to 256.5 on day 6 and 127 on day 180. CONCLUSION: In the majority of patients with acute intermediate-risk PE switched early to a direct oral anticoagulant, echocardiographic parameters of RV function normalised within 6 days and remained normal throughout the first 6 months. Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term.
Sujet(s)
Embolie pulmonaire , Dysfonction ventriculaire droite , Humains , Maladie aigüe , Échocardiographie , Pronostic , Études prospectives , Embolie pulmonaire/diagnostic , Embolie pulmonaire/traitement médicamenteux , Dysfonction ventriculaire droite/diagnostic , Dysfonction ventriculaire droite/traitement médicamenteux , Fonction ventriculaire droiteRÉSUMÉ
BACKGROUND: Atrial fibrillation (AF) is a major cause of cerebral ischemia, and its early detection may impact on health. Both invasive and non-invasive devices can be used for the diagnosis of AF. The aim of our study was to estimate the prevalence of AF using a single-lead ECG device (MyDiagnostickTM) on an adult, asymptomatic population during a screening campaign. METHODS: A total of 2547 subjects underwent AF screening. RESULTS: The device detected an arrhythmia in 42 subjects (1.65%), and AF was confirmed on 12-lead ECG in 14 (0.55%) of them. The prevalence of confirmed AF increased in subjects over 65 years of age (1.21%) or with a CHA2DS2-VASc score ≥2 in males or ≥3 in females (1.33%). Furthermore, heart failure (odds ratio [OR] 8.62, 95% confidence interval [CI] 1.87-39.6, p=0.006) and diabetes (OR 4.55, 95% CI 1.25-16.5, p=0.021) significantly increased the risk of AF. CONCLUSIONS: During a screening campaign, the diagnosis of AF increases when subjects with a high thromboembolic risk are selected.
Sujet(s)
Fibrillation auriculaire , Maladies cardiovasculaires , Accident vasculaire cérébral , Thromboembolie , Fibrillation auriculaire/diagnostic , Fibrillation auriculaire/épidémiologie , Maladies cardiovasculaires/complications , Femelle , Facteurs de risque de maladie cardiaque , Humains , Mâle , Appréciation des risques , Facteurs de risque , Accident vasculaire cérébral/prévention et contrôle , Thromboembolie/complicationsRÉSUMÉ
BACKGROUND: The COVID-19 pandemic has put several healthcare systems under severe pressure. The present analysis investigates how the first wave of the COVID-19 pandemic affected the myocardial infarction (MI) network of Emilia-Romagna (Italy). METHODS: Based on Emilia-Romagna mortality registry and administrative data from all the hospitals from January 2017 to June 2020, we analysed: i) temporal trend in MI hospital admissions; ii) characteristics, management, and 30-day mortality of MI patients; iii) out-of-hospital mortality for cardiac cause. FINDINGS: Admissions for MI declined on February 22, 2020 (IRR -19.5%, 95%CI from -8.4% to -29.3%, p = 0.001), and further on March 5, 2020 (IRR -21.6%, 95%CI from -9.0% to -32.5%, p = 0.001). The return to pre-COVID-19 MI-related admission levels was observed from May 13, 2020 (IRR 34.3%, 95%CI 20.0%-50.2%, p<0.001). As compared to those before the pandemic, MI patients admitted during and after the first wave were younger and with fewer risk factors. The 30-day mortality remained in line with that expected based on previous years (ratio observed/expected was 0.96, 95%CI 0.84-1.08). MI patients positive for SARS-CoV-2 were few (1.5%) but showed poor prognosis (around 5-fold increase in 30-day mortality). In 2020, the number of out-of-hospital cardiac deaths was significantly higher (ratio observed/expected 1.17, 95%CI 1.08-1.27). The peak was reached in April. INTERPRETATION: In Emilia-Romagna, MI hospitalizations significantly decreased during the first wave of the COVID-19 pandemic. Management and outcomes of hospitalized MI patients remained unchanged, except for those with SARS-CoV-2 infection. A concomitant increase in the out-of-hospital cardiac mortality was observed. FUNDING: None.
RÉSUMÉ
BACKGROUND: Current guidelines recommend a risk-adjusted treatment strategy for the management of acute pulmonary embolism. This is a particular patient category for whom optimal treatment (anticoagulant treatment, reperfusion strategies, and duration of hospitalisation) is currently unknown. We investigated whether treatment of acute intermediate-risk pulmonary embolism with parenteral anticoagulation for a short period of 72 h, followed by a switch to a direct oral anticoagulant (dabigatran), is effective and safe. METHODS: We did a multinational, multicentre, single-arm, phase 4 trial at 42 hospitals in Austria, Belgium, France, Germany, Italy, Netherlands, Romania, Slovenia, and Spain. Adult patients (aged ≥18 years) with symptomatic intermediate-risk pulmonary embolism, with or without deep-vein thrombosis, were enrolled. Patients received parenteral low-molecular-weight or unfractionated heparin for 72 h after diagnosis of pulmonary embolism before switching to oral dabigatran 150 mg twice per day following a standard clinical assessment. The primary outcome was recurrent symptomatic venous thromboembolism or pulmonary embolism-related death within 6 months. The primary and safety outcomes were assessed in the intention-to-treat population. The study was terminated early, as advised by the data safety and monitoring board, following sample size adaptation after the predefined interim analysis on Dec 18, 2018. This trial is registered with the EU Clinical Trials Register (EudraCT 2015-001830-12) and ClinicalTrials.gov (NCT02596555). FINDINGS: Between Jan 1, 2016, and July 31, 2019, 1418 patients with pulmonary embolism were screened, of whom 402 were enrolled and were included in the intention-to-treat analysis (median age was 69·5 years [IQR 60·0-78·0); 192 [48%] were women and 210 [52%] were men). Median follow-up was 217 days (IQR 210-224) and 370 (92%) patients adhered to the protocol. The primary outcome occurred in seven (2% [upper bound of right-sided 95% CI 3]; p<0·0001 for rejecting the null hypothesis) patients, with all events occurring in those with intermediate-high-risk pulmonary embolism (seven [3%; upper bound of right-sided 95% CI 5] of 283). At 6 months, 11 (3% [95% CI 1-5]) of 402 patients had at least one major bleeding event and 16 (4% [2-6]) had at least one clinically relevant non-major bleeding event; the only fatal haemorrhage occurred in one (<1%) patient before the switch to dabigatran. INTERPRETATION: A strategy of early switch from heparin to dabigatran following standard clinical assessment was effective and safe in patients with intermediate-risk pulmonary embolism. Our results can help to refine guideline recommendations for the initial treatment of acute intermediate-risk pulmonary embolism, optimising the use of resources and avoiding extended hospitalisation. FUNDING: German Federal Ministry of Education and Research, University Medical Center Mainz, and Boehringer Ingelheim.
Sujet(s)
Anticoagulants/usage thérapeutique , Dabigatran/usage thérapeutique , Embolie pulmonaire/traitement médicamenteux , Administration par voie orale , Sujet âgé , Sujet âgé de 80 ans ou plus , Anticoagulants/effets indésirables , Dabigatran/effets indésirables , Calendrier d'administration des médicaments , Femelle , Études de suivi , Hémorragie/étiologie , Héparine/usage thérapeutique , Humains , Mâle , Adulte d'âge moyen , Embolie pulmonaire/complications , Facteurs de risque , Résultat thérapeutique , Thromboembolisme veineux/complicationsRÉSUMÉ
BACKGROUND: In patients with an indication for oral anticoagulation (OAC) with warfarin, the management of OAC peri-procedure of percutaneous coronary intervention (PCI) is still not fully defined. To investigate clinical practice and outcomes associated with continuation vs interruption of OAC, with or without bridging with low-molecular-weight heparin (LMWH), we examined the database of the observational, prospective, multicenter Italian WAR-STENT registry. METHODS: The WAR-STENT registry was conducted in 2008-2010 in 37 Italian centers and included 411 consecutive patients in 157 of whom the peri-procedural international normalized ratio (INR) value was available. In relation to the continuation vs interruption of OAC, patients were divided into group 1 (n = 106) and group 2 (n = 51) respectively, and compared. RESULTS: The basal characteristics of the two groups were similar. The most frequent indication for OAC was atrial fibrillation and for PCI acute coronary syndromes, respectively. The pre-procedural mean value of INR was significantly different in group 1 vs group 2 (2.3 ± 0.4 vs 1.5 ± 0.2; p <0.001), while the use of antithrombotic drugs did not differ, except for LMWH which, albeit limited to only 14% of cases, was used significantly more frequently in group 2 (14% vs 2%; p=0.006). The radial approach was used significantly more often in group 1 vs group 2 (72% vs 45%; p=0.002). The in-hospital incidence of major bleeding complications was similar in groups 1 and 2 (4% vs 8%; p=0.27), as well as the occurrence of major adverse cardio-cerebrovascular events, including cardiovascular death, non-fatal myocardial infarction, re-revascularization of the treated vessel, stent thrombosis, stroke and venous thromboembolism (6% vs 6%; p=0.95). There was a tendency towards a higher incidence of minor access-site bleeding complications in group 1 patients treated by the femoral route. CONCLUSIONS: In unselected patients with an indication for OAC with warfarin and undergoing PCI, the continuation vs interruption of OAC (essentially without LMWH bridging) strategies appears similar in terms of efficacy and safety. In consideration of the superior convenience, peri-procedural continuation of OAC should therefore generally be preferred, with the possible exception of patients in whom the femoral approach is required for the procedure.
Sujet(s)
Fibrillation auriculaire , Intervention coronarienne percutanée , Administration par voie orale , Anticoagulants/effets indésirables , Fibrillation auriculaire/traitement médicamenteux , Héparine bas poids moléculaire , Hôpitaux , Humains , Études prospectives , Enregistrements , Endoprothèses , Résultat thérapeutique , WarfarineRÉSUMÉ
AIMS: The purpose of this study was to verify the impact on the number and characteristics of coronary invasive procedures for acute coronary syndrome (ACS) of two hub centers with cardiac catheterization facilities, during the first month of lockdown following the COVID-19 pandemic. MATERIALS AND METHODS: Procedural data of ACS patients admitted between 10 March and 10 April 2020 were compared with those of the same period of 2019. RESULTS: We observed a 23.4% reduction in ACS admissions during 2020, with a decrease for both ST-elevation myocardial infarction (STEMI) (-5.6%) and non-ST-elevation myocardial infarction (-34.5%), albeit not statistically significant (Pâ=â0.2). During the first 15 days of the examined periods, the reduction in ACS admissions reached 52.5% (-25% for STEMI and -70.3% for non-ST-elevation myocardial infarction, Pâ=â0.04). Among STEMI patients, the rate of those with a time delay from symptoms onset longer than 180âmin was significantly higher during the lockdown period (Pâ=â0.01). Radiograph exposure (Pâ=â0.01) was higher in STEMI patients treated in 2020 with a slightly higher amount of contrast medium (Pâ=â0.1) and number of stents implanted (Pâ=â0.1), whereas the number of treated vessels was reduced (Pâ=â0.03). Percutaneous coronary intervention procedural success and in-hospital mortality were not different between the two groups and in STEMI patients (P NS for all). CONCLUSION: During the early phase, the COVID-19 outbreak was associated with a lower rate of admissions for ACS, with a substantial impact on the time delay presentation of STEMI patients, but apparently without affecting the in-hospital outcomes.
Sujet(s)
Syndrome coronarien aigu , Infections à coronavirus , Hospitalisation/statistiques et données numériques , Infarctus du myocarde , Pandémies , Intervention coronarienne percutanée , Pneumopathie virale , Syndrome coronarien aigu/diagnostic , Syndrome coronarien aigu/épidémiologie , Syndrome coronarien aigu/étiologie , Syndrome coronarien aigu/thérapie , Betacoronavirus , COVID-19 , Infections à coronavirus/épidémiologie , Infections à coronavirus/prévention et contrôle , Retard de diagnostic/statistiques et données numériques , Femelle , Mortalité hospitalière , Humains , Prévention des infections/méthodes , Italie/épidémiologie , Mâle , Adulte d'âge moyen , Infarctus du myocarde/complications , Infarctus du myocarde/diagnostic , Infarctus du myocarde/mortalité , Infarctus du myocarde/chirurgie , Évaluation des résultats et des processus en soins de santé , Pandémies/prévention et contrôle , Intervention coronarienne percutanée/effets indésirables , Intervention coronarienne percutanée/méthodes , Intervention coronarienne percutanée/statistiques et données numériques , Pneumopathie virale/épidémiologie , Pneumopathie virale/prévention et contrôle , SARS-CoV-2 , Délai jusqu'au traitement/statistiques et données numériquesRÉSUMÉ
AIMS: Our aim was to describe the electrocardiographic features of critical COVID-19 patients. METHODS AND RESULTS: We carried out a multicentric, cross-sectional, retrospective analysis of 431 consecutive COVID-19 patients hospitalized between 10 March and 14 April 2020 who died or were treated with invasive mechanical ventilation. This project is registered on ClinicalTrials.gov (identifier: NCT04367129). Standard ECG was recorded at hospital admission. ECG was abnormal in 93% of the patients. Atrial fibrillation/flutter was detected in 22% of the patients. ECG signs suggesting acute right ventricular pressure overload (RVPO) were detected in 30% of the patients. In particular, 43 (10%) patients had the S1Q3T3 pattern, 38 (9%) had incomplete right bundle branch block (RBBB), and 49 (11%) had complete RBBB. ECG signs of acute RVPO were not statistically different between patients with (n = 104) or without (n=327) invasive mechanical ventilation during ECG recording (36% vs. 28%, P = 0.10). Non-specific repolarization abnormalities and low QRS voltage in peripheral leads were present in 176 (41%) and 23 (5%), respectively. In four patients showing ST-segment elevation, acute myocardial infarction was confirmed with coronary angiography. No ST-T abnormalities suggestive of acute myocarditis were detected. In the subgroup of 110 patients where high-sensitivity troponin I was available, ECG features were not statistically different when stratified for above or below the 5 times upper reference limit value. CONCLUSIONS: The ECG is abnormal in almost all critically ill COVID-19 patients and shows a large spectrum of abnormalities, with signs of acute RVPO in 30% of the patients. Rapid and simple identification of these cases with ECG at hospital admission can facilitate classification of the patients and provide pathophysiological insights.
Sujet(s)
Troubles du rythme cardiaque/physiopathologie , Troubles du rythme cardiaque/virologie , COVID-19/complications , Maladie grave , Électrocardiographie , Sujet âgé , Sujet âgé de 80 ans ou plus , Marqueurs biologiques/sang , COVID-19/épidémiologie , Études transversales , Femelle , Hospitalisation/statistiques et données numériques , Humains , Italie/épidémiologie , Mâle , Adulte d'âge moyen , Pandémies , Ventilation artificielle , Études rétrospectives , SARS-CoV-2Sujet(s)
Troubles du rythme cardiaque , Azithromycine , Infections à coronavirus , Hospitalisation/statistiques et données numériques , Hydroxychloroquine , Pandémies , Pneumopathie virale , Anti-infectieux/administration et posologie , Anti-infectieux/effets indésirables , Troubles du rythme cardiaque/diagnostic , Troubles du rythme cardiaque/étiologie , Azithromycine/administration et posologie , Azithromycine/effets indésirables , Betacoronavirus , COVID-19 , Dépistage de la COVID-19 , Techniques de laboratoire clinique/méthodes , Infections à coronavirus/diagnostic , Infections à coronavirus/traitement médicamenteux , Infections à coronavirus/épidémiologie , Infections à coronavirus/physiopathologie , Effets secondaires indésirables des médicaments/diagnostic , Humains , Hydroxychloroquine/administration et posologie , Hydroxychloroquine/effets indésirables , Italie/épidémiologie , , Pneumopathie virale/diagnostic , Pneumopathie virale/traitement médicamenteux , Pneumopathie virale/épidémiologie , Pneumopathie virale/physiopathologie , SARS-CoV-2 , Délai jusqu'au traitement , Traitements médicamenteux de la COVID-19RÉSUMÉ
BACKGROUND AND AIMS: Familial hypercholesterolaemia (FH) is a powerful risk factor for cardiovascular (CV) events. High levels of low-density lipoprotein cholesterol (LDL-C) since birth are linked to the early onset of atherosclerotic disease. A genetic mutation determining FH is present in about one subject out of 250; FH should be more represented among subjects with a documented diagnosis of coronary artery disease (CAD). The POSTER Study evaluated the prevalence of FH in Italian patients with a recent CAD event. METHODS: Eighty-two cardiology centres enrolled patients with a documented CAD event; CV risk profile, drug therapy and biochemical parameters were collected. Dutch Lipid Clinic Network (DLCN) criteria were used to define patients with a potential FH diagnosis (score ≥6); these patients underwent molecular testing for genetic diagnosis of FH. RESULTS: Overall, 5415 patients were enrolled and the main index events were myocardial infarction with ST-elevation, non ST-elevation acute coronary syndrome (ACS), or a recent coronary revascularization (34.8%, 37.2%, and 28% respectively). Mean age was 66 ± 11 years, men were 78%; about 40% were already treated with statins, proportion that increased after the acute event (96.5%). Based on the DLCN score, the prevalence of potential FH was 5.1%, 0.9% of them had a diagnosis of definite FH (score >8). These patients were younger than patients with a score <6 (56 ± 10 vs 66 ± 11, p < 0.001), and LDL-C levels were in most of them (~87%) >190 mg/dL. FH was genetically confirmed in 42 subjects (15.9%); genetic diagnosis was defined as not conclusive for FH in 63 patients (23.9%). Finally, in 159 subjects (60.2%) no pathogenic mutations in the tested genes were identified, defining them as negative for monogenic familial hypercholesterolemia. CONCLUSIONS: Results underscore a relatively high prevalence of potential FH in patients with a recent CAD event. Therefore, an early identification of these subjects may help improve the management of their high CV risk and, by cascade screening, identify possible FH relatives.
Sujet(s)
Maladie des artères coronaires , Hyperlipoprotéinémie de type II , Sujet âgé , Cholestérol LDL , Maladie des artères coronaires/diagnostic , Maladie des artères coronaires/épidémiologie , Maladie des artères coronaires/génétique , Humains , Hyperlipoprotéinémie de type II/diagnostic , Hyperlipoprotéinémie de type II/traitement médicamenteux , Hyperlipoprotéinémie de type II/épidémiologie , Italie/épidémiologie , Mâle , Adulte d'âge moyen , Prévalence , Facteurs de risqueRÉSUMÉ
Cardiomyopathies are a heterogeneous group of cardiac diseases for which diagnosis and treatment are not always simple. The diagnosis of cardiomyopathy, in particular the etiology, comes from an integration between symptoms and results collected by several instrumental exams. The brain storming for the diagnosis includes also the identification of the "red flags", i.e. the pathognomonic features for each etiology that can drive the choice of appropriate diagnostic tests and therapy. In this review, we provide a step by step approach in order to help cardiologists, not specifically dedicated to cardiomyopathies, to draw the diagnosis, therapy and follow-up. This approach will be accompanied by the consultation of other specialists to discuss together the results of the exams performed and to deepen extracardiac signs and symptoms.
Sujet(s)
Cardiomyopathies/diagnostic , Cardiomyopathies/génétique , Phénotype , Évaluation des symptômes , Dysplasie ventriculaire droite arythmogène/diagnostic , Dysplasie ventriculaire droite arythmogène/génétique , Dysplasie ventriculaire droite arythmogène/thérapie , Cardiomyopathies/thérapie , Cardiomyopathie dilatée/diagnostic , Cardiomyopathie dilatée/génétique , Cardiomyopathie dilatée/thérapie , Cardiomyopathie hypertrophique/diagnostic , Cardiomyopathie hypertrophique/génétique , Cardiomyopathie hypertrophique/thérapie , Cardiomyopathie restrictive/diagnostic , Cardiomyopathie restrictive/étiologie , Cardiomyopathie restrictive/thérapie , Diagnostic différentiel , Échocardiographie , Électrocardiographie , Humains , IRM dynamique , Tomographie par émission de positons , Orientation vers un spécialiste , Sarcoïdose/diagnosticRÉSUMÉ
BACKGROUND: The present study aimed at describing (i) the characteristics of non-valvular atrial fibrillation (NVAF) patients newly treated with oral anticoagulants (vitamin K antagonists [VKA] or new oral anticoagulants [NOAC]), and (ii) their persistence to treatment assigned, clinical outcomes (bleeding and thromboembolic events) and mortality. METHODS: This study was conducted using administrative databases of an Italian Local Health Unit. All adult patients (aged ≥18 years) with NVAF and naïve to VKA (warfarin) or NOAC (rivaroxaban, apixaban, dabigatran) were included between January 1, 2014 and June 30, 2015. Propensity score matching was performed to check for confounding effects. Included patients were characterized for comorbidities, CHA2DS2-VASc and HAS-BLED score, antiplatelet drug use and followed up for at least 12 months to assess persistence to treatment and incidence of clinical outcomes. RESULTS: A total of 970 NVAF patients newly treated with oral anticoagulants were included; 595 (61.3%) received VKA and 375 (38.7%) NOAC. VKA naïve patients had a lower low and intermediate score for HAS-BLED and CHA2DS2-VASc compared to NOAC patients. Overall, 80.6% of naïve NAO patients and 73.4% of naïve AVK patients were persistent to treatment. Incidence of bleeding events was slightly higher in VKA patients (3.13/100 persons year) compared to NOAC patients (2.73/100 persons years), as well as incidence of thromboembolic events (3.48/100 persons year and 2.18/100 persons year, respectively). After propensity score matching no differences were observed. CONCLUSIONS: The majority of NVAF patients newly treated with oral anticoagulants received VKA-based therapy. Incidence of bleeding and thromboembolic events was slightly higher in VKA patients compared to NOAC patients.
Sujet(s)
Anticoagulants/effets indésirables , Fibrillation auriculaire/complications , Accident vasculaire cérébral/prévention et contrôle , Administration par voie orale , Sujet âgé , Anticoagulants/administration et posologie , Antithrombiniques/administration et posologie , Antithrombiniques/effets indésirables , Cause de décès , Comorbidité , Dabigatran/administration et posologie , Dabigatran/effets indésirables , Bases de données factuelles , Femelle , Hémorragie/induit chimiquement , Humains , Mâle , Adhésion au traitement médicamenteux/statistiques et données numériques , Antiagrégants plaquettaires/administration et posologie , Antiagrégants plaquettaires/effets indésirables , Score de propension , Pyrazoles/administration et posologie , Pyrazoles/effets indésirables , Pyridones/administration et posologie , Pyridones/effets indésirables , Études rétrospectives , Rivaroxaban/administration et posologie , Rivaroxaban/effets indésirables , Accident vasculaire cérébral/étiologie , Thromboembolie/induit chimiquement , Warfarine/administration et posologie , Warfarine/effets indésirablesRÉSUMÉ
Coronary chronic total occlusion (CTO) produces an important clinical problem, often treated with medical therapy or coronary artery bypass grafting. Recent clinical studies, both registries and randomized trials, demonstrated that percutaneous coronary interventions (PCI), could provide a valid therapeutic option. Nonetheless, significant reduction in all-cause mortality, cardiac mortality, myocardial infarction, MACE, and MACCE has not been demonstrated in the subgroups analysis of randomized trials. These analyses suggest that PCI for CTO should be reserved for patients with angina or with large areas of the myocardium with reversible ischaemia. Large randomized studies should search for a personalized approach, considering the risks and complexity of PCI in CTO, which should mainly consider the extension of the ischaemia and the viability of the myocardium.
RÉSUMÉ
To date, aspirin desensitization is employed with patients with nonsteroidal anti-inï¬ammatory drugs (NSAIDs) exacerbated respiratory diseases (NERD) or with aspirin or NSAIDs hypersensitive patients needing a stent procedure for coronary artery disease. On the other hand, few data exist regarding aspirin desensitization in other cardiological features and particularly we haven't data on different NSAIDs desensitization. Only for NERD patients we have data on ketorolac use. We report an efficacious desensitization procedure for ibuprofen in urticaria/angioedema patient with pericarditis and myocarditis associated.
Sujet(s)
Anti-inflammatoires non stéroïdiens/administration et posologie , Désensibilisation immunologique/méthodes , Hypersensibilité médicamenteuse/prévention et contrôle , Ibuprofène/administration et posologie , Myocardite/traitement médicamenteux , Adulte , Anti-inflammatoires non stéroïdiens/effets indésirables , Anti-inflammatoires non stéroïdiens/immunologie , Calendrier d'administration des médicaments , Hypersensibilité médicamenteuse/diagnostic , Hypersensibilité médicamenteuse/immunologie , Humains , Ibuprofène/effets indésirables , Ibuprofène/immunologie , Mâle , Myocardite/diagnostic , Myocardite/immunologie , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Elderly patients are at elevated risk of both ischemic and bleeding complications after an acute coronary syndrome and display higher on-clopidogrel platelet reactivity compared with younger patients. Prasugrel 5 mg provides more predictable platelet inhibition compared with clopidogrel in the elderly, suggesting the possibility of reducing ischemic events without increasing bleeding. METHODS: In a multicenter, randomized, open-label, blinded end point trial, we compared a once-daily maintenance dose of prasugrel 5 mg with the standard clopidogrel 75 mg in patients >74 years of age with acute coronary syndrome undergoing percutaneous coronary intervention. The primary end point was the composite of mortality, myocardial infarction, disabling stroke, and rehospitalization for cardiovascular causes or bleeding within 1 year. The study was designed to demonstrate superiority of prasugrel 5 mg over clopidogrel 75 mg. RESULTS: Enrollment was interrupted, according to prespecified criteria, after a planned interim analysis, when 1443 patients (40% women; mean age, 80 years) had been enrolled with a median follow-up of 12 months, because of futility for efficacy. The primary end point occurred in 121 patients (17%) with prasugrel and 121 (16.6%) with clopidogrel (hazard ratio, 1.007; 95% confidence interval, 0.78-1.30; P=0.955). Definite/probable stent thrombosis rates were 0.7% with prasugrel versus 1.9% with clopidogrel (odds ratio, 0.36; 95% confidence interval, 0.13-1.00; P=0.06). Bleeding Academic Research Consortium types 2 and greater rates were 4.1% with prasugrel versus 2.7% with clopidogrel (odds ratio, 1.52; 95% confidence interval, 0.85-3.16; P=0.18). CONCLUSIONS: The present study in elderly patients with acute coronary syndromes showed no difference in the primary end point between reduced-dose prasugrel and standard-dose clopidogrel. However, the study should be interpreted in light of the premature termination of the trial. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01777503.
Sujet(s)
Syndrome coronarien aigu/mortalité , Syndrome coronarien aigu/thérapie , Clopidogrel/administration et posologie , Infarctus du myocarde/mortalité , Infarctus du myocarde/thérapie , Chlorhydrate de prasugrel/administration et posologie , Sujet âgé , Sujet âgé de 80 ans ou plus , Clopidogrel/effets indésirables , Survie sans rechute , Femelle , Hémorragie/induit chimiquement , Hémorragie/mortalité , Humains , Mâle , Intervention coronarienne percutanée , Chlorhydrate de prasugrel/effets indésirables , Taux de survieRÉSUMÉ
OBJECTIVES: To define the incidence of vascular complications (VC) after balloon aortic valvuloplasty (BAV) in recent years, and to compare the performance of two vascular closure devices (VCD). BACKGROUND: VC remain the most frequent drawback of BAV and are associated with adverse clinical outcomes. METHODS: All BAV procedures performed at 2 high-volume centers over a 6-year period (n = 930) were collected in prospective registries and investigated to assess the incidence of Valve Academic Research Consortium-2 (VARC-2) defined VC. Incidence of life-threatening, major and minor bleeding was also assessed. In-hospital major adverse cardiac and cerebrovascular events (MACCE) rate (composite of in-hospital death, myocardial infarction, TIA/stroke, and life-threatening bleeding) as well as 30-day survival was compared between a suture-mediated closure system and a collagen plug hemostatic device. RESULTS: A 9 Fr arterial sheath was used in most of the patients (84.1%). Vascular closure was obtained with the Angio-Seal in 643 patients (69.1%) and the ProGlide in 287 (30.9%). The overall incidence of major VC was 2.7%, and minor VC 6.6%, without significant differences between groups. The Angio-Seal group was associated with a higher rate of small hematomas (6.9% vs. 3.5%, P = 0.042), whilst blood transfusions were more frequent in the ProGlide group (6.6% vs. 3.5%, P = 0.034). Rates of in-hospital MACCE and 30-day survival were similar. Use of either VCD was not independently associated with major VC. CONCLUSIONS: VC rate after BAV is fairly low in experienced centers without major differences between the 2 most used VCD.
Sujet(s)
Sténose aortique/thérapie , Valvuloplastie par ballonnet/effets indésirables , Maladies cardiovasculaires/épidémiologie , Hémorragie/prévention et contrôle , Techniques d'hémostase/effets indésirables , Techniques d'hémostase/instrumentation , Techniques de suture/effets indésirables , Techniques de suture/instrumentation , Matériaux de suture , Dispositifs de fermeture vasculaire , Sujet âgé , Sujet âgé de 80 ans ou plus , Sténose aortique/diagnostic , Sténose aortique/mortalité , Valvuloplastie par ballonnet/mortalité , Maladies cardiovasculaires/diagnostic , Maladies cardiovasculaires/mortalité , Conception d'appareillage , Femelle , Hémorragie/diagnostic , Hémorragie/mortalité , Techniques d'hémostase/mortalité , Hôpitaux à haut volume d'activité , Humains , Incidence , Italie , Mâle , Enregistrements , Facteurs de risque , Indice de gravité de la maladie , Techniques de suture/mortalité , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
PURPOSE: To evaluate the outcome of patients with an established indication for oral anticoagulation (OAC) undergoing coronary stent implantation (PCI-S) and stratified by the baseline risk of bleeding. MATERIAL AND METHODS: The database of the prospective, multicentre, observational WAR-STENT registry (ClinicalTrials.gov identifier NCT00722319) was analyzed and patients with atrial fibrillation and CHA2DS2-VASc score ≥2, mechanical heart valve, prior cardiac embolism, intra-cardiac thrombus and recent venous thromboembolism who were treated with either triple (warfarin, aspirin and clopidogrel) or dual (warfarin and clopidogrel) or dual antiplatelet (aspirin and clopidogrel) therapy, identified. Patients were then sorted into two groups at non-low and low risk of bleeding, as defined by an ATRIA score >3 and ≤3 respectively, and compared regarding major adverse cardiac and vascular events (MACVE) and bleeding. RESULTS: At 12-month follow up, MACVE were comparable in the two groups, whereas total, major and minor bleeding, as well as combined MACVE and total bleeding, were significantly more frequent in the non-low bleeding risk group. Upon Cox univariate and multivariable analysis, non-low bleeding risk category confirmed as an independent predictor of major bleeding. The choice of antithrombotic therapy however, appeared not to be influenced by the bleeding risk category at baseline. CONCLUSIONS: In patients with an established indication for OAC undergoing PCI-S, non-low bleeding risk category is the most potent independent predictor of major bleeding. Stratification of the bleeding risk at baseline should therefore be regarded as an indispensable process to be carried out before selection of the antithrombotic therapy.
Sujet(s)
Anticoagulants/usage thérapeutique , Maladie des artères coronaires/chirurgie , Hémorragie/prévention et contrôle , Antiagrégants plaquettaires/usage thérapeutique , Endoprothèses , Ticlopidine/analogues et dérivés , Warfarine/usage thérapeutique , Administration par voie orale , Adulte , Sujet âgé , Anticoagulants/administration et posologie , Clopidogrel , Femelle , Humains , Mâle , Adulte d'âge moyen , Études prospectives , Enregistrements , Endoprothèses/effets indésirables , Traitement thrombolytique , Ticlopidine/administration et posologie , Ticlopidine/usage thérapeutique , Résultat thérapeutique , Warfarine/administration et posologie , Jeune adulteSujet(s)
Cardiopathies congénitales , Adulte , Prise en charge de la maladie , Femelle , Humains , Grossesse , Sports/physiologieRÉSUMÉ
The causes of death within 1 year of hospital admission in patients with non-ST-segment elevation acute coronary syndromes are ill defined, particularly in patients aged ≥75 years. From January 2008 through May 2010, we enrolled 645 patients aged ≥75 years with non-ST-segment elevation acute coronary syndromes: 313 in a randomized trial comparing an early aggressive versus an initially conservative approach, and 332, excluded from the trial for specific reasons, in a parallel registry. Each death occurring during 1 year of follow-up was adjudicated by an independent committee. The mean age was 82 years in both study cohorts, and 53% were men. By the end of the follow-up period (median 369 days, interquartile range 345 to 391), 120 patients (18.6%) had died. The mortality was significantly greater in the registry (23.8% vs 13.1%, p = 0.001). The deaths were classified as cardiac in 94% of the cases during the index admission and 68% of the cases during the follow-up period. Eighty-six percent of the cardiac deaths were of ischemic origin. In a multivariate logistic regression model that included the variables present on admission in the whole study population, the ejection fraction (hazard ratio 0.95, 95% confidence interval 0.94 to 0.97; p <0.001), hemoglobin level (hazard ratio 0.85, 95% confidence interval 0.76 to 0.94; p = 0.001), older age (hazard ratio 1.05, 95% confidence interval 1.01 to 1.10, p = 0.010), and creatinine clearance (hazard ratio 0.99, 95% confidence interval 0.97 to 0.99; p = 0.030) were the independent predictors of all-cause death at 1 year. In conclusion, within 1 year after admission for non-ST-segment elevation acute coronary syndromes, most deaths in patients aged ≥75 years have a cardiac origin, mostly owing to myocardial ischemia.